The use of cytochrome-P450-dependent 5 hydroxylation inhibitor in combination with an antiarrhythmic for the treatment of paroxysmal atrial fibrillation
Professor Lau, Chu Pak (Principal investigator)
Professor Chow (Co-Investigator)
RGC General Research Fund (GRF)
HKU Project Code
General Research Fund (GRF)
To assess the incidence polymorphic oxidative metabolism of propafenone in Chinese patients (Phase 1); to evaulate the relative efficacy of a cytochrome-P450-dependent 5-hydroxylation (CDH) inhibitor (using low dose quinidine) in combination with standard dose propafenone versus high dose propafenone in the management of patients with PAF refractory to standard doses of propafenone (Phase 2 and 3); to assess the efficacy of regular dose quinidine in combination with standard dose propafenone in an open label treatment in patients resistant to Phase 2 and 3 (Phase 4).